Experience with long-term use of epoetin alfa for the correction of anemia in patients on program hemodialysis

Pushkina A.V., Fesyuk A.A.

OOO FESFARM COMPANY, Moscow, Russia

Objective. Evaluation of the efficacy of long-term use of epoetin alfa for the correction of anemia in patients on program hemodialysis (HD).
Material and Methods. A retrospective analysis of anemia treatment in patients on program HD was conducted. The study included patients treated with epoetin alfa in 0.25 ml syringes at a dose of 2500 IU.
Results. Over a 4-year follow-up period, mean hemoglobin, ferritin, and transferrin saturation levels increased statistically significantly, while the epoetin alfa dose and erythropoietin resistance index decreased statistically significantly.
Conclusion. The results of long-term use of epoetin alfa at a single dose of 2500 IU for the correction of anemia in dialysis patients demonstrated its high efficacy and safety. Maintaining optimal iron stores in the body is an important prerequisite for successful anemia correction.

Keywords

About the Authors

Anna V. Pushkina – Chief Physician, OOO FESFARM COMPANY. Address: Office 27, Bldg. 3, 10 Neverovsky st, Moscow, 121170;
e-mail: avpushkina@yandex.ru. ORCID: 0000-0003-1560-7289.
Anna A. Fesyuk – Deputy General Director for Medical Affairs, OOO FESFARM COMPANY. Address: Office 27, Bldg. 3, 10 Neverovsky st, Moscow, 121170;
e-mail: faa001@mail.ru. ORCID: 0009-0000-2714-0271

Similar Articles